Tagala, Pablito L.
HRN: 23-01-53 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/10/2023
CEFTAZIDIME 1GM (VIAL)
05/10/2023
05/17/2023
IV
1gm
Q8
CAP-MR
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes